The diagnostic odyssey for rare disease patients is one of modern medicine's most frustrating realities: an estimated 6,000-10,000 rare diseases affect 300 million people globally, yet more than half remain without molecular answers after exhaustive DNA testing. The MedicalXpress coverage of CHOP's new STRIPE platform rightly celebrates its success in resolving five previously undiagnosed cases of congenital disorders of glycosylation (CDG) and primary mitochondrial diseases (PMD). However, it stops short of contextualizing this within the larger shift toward functional genomics, underplays the study's modest scale, and misses critical connections to parallel efforts that suggest RNA sequencing could systematically raise diagnostic yields from the current 20-50% ceiling.

Published in Science Advances (April 2026), the CHOP team's work represents a peer-reviewed methodological advance rather than a large-scale clinical trial. The observational study applied their targeted long-read RNA sequencing approach—built on the earlier TEQUILA-seq technology—to clinically accessible tissues like skin fibroblasts and blood from patients with suspected CDG and PMD. By achieving deep coverage of full-length transcripts at roughly $100 per sample, STRIPE overcomes key limitations of both short-read RNA-seq (which fragments molecules, losing haplotype phasing) and untargeted long-read methods (prohibitively expensive at scale). The platform directly visualizes splicing defects, allele-specific expression, and nonsense-mediated decay—functional consequences invisible to exome or genome sequencing alone.

What the original reporting missed is the platform's potential to illuminate epigenetic and cis-regulatory effects that standard DNA tests systematically ignore. A 2022 Nature Medicine paper by Fresard et al. (n=184 rare disease patients, observational cohort, no declared COIs) previously showed that RNA-seq on fibroblasts and blood could provide diagnoses or candidate genes in 16% of cases where DNA sequencing was inconclusive. STRIPE builds on this by adding long-read resolution, allowing researchers to link distant variants on the same molecule—an advance also echoed in a 2024 Genome Biology study from the Undiagnosed Diseases Network (UDN) that integrated long-read RNA data across 92 families, identifying pathogenic splicing events missed by short-read approaches in 7 cases.

The patterns are clear: we have moved beyond variant identification to functional validation. The NIH's Undiagnosed Diseases Network has repeatedly documented that 70-80% of undiagnosed patients have variants that disrupt RNA processing. Traditional coverage rarely connects this CHOP work to emerging multi-omics pipelines now being piloted in academic centers, where combining long-read RNA with proteome and metabolome data is beginning to end diagnostic odysseys that average 5-7 years and cost over $100,000 per patient. STRIPE's targeted design is both its strength and a limitation the original article glossed over—it excels for curated gene panels but requires clinicians to know which genes to interrogate, potentially missing novel disease genes outside the panel.

Study limitations must be noted: the CHOP cohort was small (specific n not detailed beyond the five resolved cases), tissue-specific RNA expression means blood or fibroblast data won't capture all neurological or cardiac phenotypes, and variant interpretation still requires substantial bioinformatics expertise. No conflicts were reported, but the technology's inventors serving as senior authors (Yi Xing and Lan Lin) calls for rapid independent replication. Despite these caveats, the editorial lens holds: this is a major precision medicine advance. If scaled, even a conservative additional 15% diagnostic yield could resolve tens of thousands of cases annually in the US alone, shifting rare disease care from perpetual uncertainty to actionable molecular diagnoses and enabling antisense oligonucleotide or small-molecule therapies tailored to specific RNA defects.

The original source also failed to explore equity implications. Long-read technologies have historically been confined to well-resourced centers; STRIPE's cost-effectiveness may democratize access, yet implementation science studies are now needed to integrate it into standard clinical pipelines. In synthesis, the CHOP innovation, read alongside the Fresard and UDN papers, signals that the era of DNA-only diagnostics is ending. Functional RNA interrogation is becoming indispensable, offering not just diagnoses but mechanistic insights that accelerate therapy development. For thousands of families, the end of their diagnostic odyssey may finally be in sight.